Cover Story
Regulatory News
The FDA Oncologic Drugs Advisory Committee agreed with the agency’s forcefully stated view that Lynparza (olaparib), a PARP inhibitor, should be given only to metastatic castration-resistant prostate cancer patients whose tumors have a BRCA mutation.
In Brief
Funding Opportunities
Clinical Roundup
Drugs & Targets
NCI Trials
NCI Trials for May 2023
The National Cancer Institute approved the following clinical research studies last month.
Trending Stories
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- “This is our time, and the time is now”—Chapman tells us about Jefferson’s final push for Comprehensive designation
- Leading a Comprehensive Cancer Center—one job or two?
- Call to action: To address Black cancer disparities, focus on research prioritization and clinical studies inclusion
Minority Cancer Awareness Week - Rathmell: To improve funding outlook, we must reverse distrust in science